Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Zydus Lifesciences Ltd.
Change Company   
BSE Code 532321
ISIN Demat INE010B01027
Book Value 214.41
NSE Code ZYDUSLIFE
Dividend Yield % 1.06
Market Cap 1040043.45
P/E 23.33
EPS 44.31
Face Value 1  
16-Sep-2025 Zydus Lifesciences’ arm launches first veterinary...
16-Sep-2025 Zydus Lifesciences’ arm launches generic of pheny...
16-Sep-2025 Zydus Lifesciences moves up as its arm launches g...
06-Sep-2025 USFDA completes inspection at Zydus group’s injec...
05-Sep-2025 Zydus Lifesciences soars as its arm inks licensin...
04-Sep-2025 Zydus Lifesciences’ arm inks licensing, supply ag...
02-Sep-2025 Zydus Lifesciences launches VaxiFlu in India
29-Aug-2025 Zydus Lifesciences’ arm reports positive topline ...
26-Aug-2025 Zydus Lifesciences informs about ESG rating
14-Aug-2025 USFDA concludes inspection at Zydus Lifesciences’...
14-Aug-2025 USFDA conducts inspection at Zydus group’s formul...
13-Aug-2025 Zydus Lifesciences reports 3% rise in Q1 consolid...
11-Aug-2025 Zydus Lifesciences gets USFDA’s final approval fo...
11-Aug-2025 Zydus Lifesciences surges on getting USFDA’s fina...
07-Aug-2025 Zydus Lifesciences gets NoC for ZDS-Varenicline T...
Page 1 of 6
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.